Bicara Therapeutics (NASDAQ:BCAX) Upgraded at Wedbush

Wedbush upgraded shares of Bicara Therapeutics (NASDAQ:BCAX) to a strong-buy rating in a research note released on Wednesday morning,Zacks.com reports.

BCAX has been the topic of a number of other research reports. Cantor Fitzgerald started coverage on Bicara Therapeutics in a research note on Tuesday, October 8th. They issued an “overweight” rating on the stock. TD Cowen began coverage on Bicara Therapeutics in a report on Tuesday, October 8th. They set a “buy” rating on the stock. Morgan Stanley assumed coverage on Bicara Therapeutics in a research note on Tuesday, October 8th. They issued an “overweight” rating and a $35.00 target price for the company. RODMAN&RENSHAW raised shares of Bicara Therapeutics to a “strong-buy” rating in a research note on Tuesday, November 5th. Finally, Stifel Nicolaus assumed coverage on shares of Bicara Therapeutics in a research note on Tuesday, October 8th. They issued a “buy” rating and a $47.00 price objective for the company. Six research analysts have rated the stock with a buy rating and two have issued a strong buy rating to the company. According to data from MarketBeat, the company currently has an average rating of “Buy” and a consensus price target of $41.20.

Bicara Therapeutics Price Performance

Bicara Therapeutics stock opened at $12.13 on Wednesday. The business’s 50-day simple moving average is $15.84. Bicara Therapeutics has a 52 week low of $11.10 and a 52 week high of $28.09.

Bicara Therapeutics (NASDAQ:BCAX) last announced its earnings results on Tuesday, November 12th. The company reported ($1.60) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.46) by ($1.14). As a group, equities research analysts predict that Bicara Therapeutics will post -2.59 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Bicara Therapeutics

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Spire Wealth Management bought a new stake in Bicara Therapeutics in the 4th quarter worth $31,000. SG Americas Securities LLC bought a new stake in shares of Bicara Therapeutics in the fourth quarter worth about $147,000. Cinctive Capital Management LP purchased a new position in Bicara Therapeutics during the 3rd quarter valued at about $229,000. Barclays PLC bought a new position in Bicara Therapeutics during the 3rd quarter valued at approximately $255,000. Finally, Jane Street Group LLC bought a new stake in shares of Bicara Therapeutics in the 3rd quarter worth approximately $309,000.

About Bicara Therapeutics

Bicara Therapeutics Inc, a clinical-stage biopharmaceutical company, develops bifunctional therapies for solid tumors. Its lead program is ficerafusp alfa, a bifunctional antibody that combines an epidermal growth factor receptor (EGFR) directed monoclonal antibody with a domain that binds to human transforming growth factor beta (TGF-b) for the treatment of solid tumors.